Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이민형 | - |
dc.date.accessioned | 2017-03-17T00:47:28Z | - |
dc.date.available | 2017-03-17T00:47:28Z | - |
dc.date.issued | 2015-07 | - |
dc.identifier.citation | JOURNAL OF PHARMACEUTICAL SCIENCES, v. 104, NO 11, Page. 3743-3751 | en_US |
dc.identifier.issn | 0022-3549 | - |
dc.identifier.issn | 1520-6017 | - |
dc.identifier.uri | http://onlinelibrary.wiley.com/doi/10.1002/jps.24576/full | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/26168 | - |
dc.description.abstract | Gene therapy has been considered as an alternative treatment for glioblastoma therapy. In this study, a glioblastoma-specific suicide gene, pEpo-NI2-SV-TK, was delivered into the intracranial glioblastoma model using reducible poly(oligo-d-arginines) (rPOA). pEpo-NI2-SV-TK has the erythropoietin (Epo) enhancer and the nestin intron 2 (NI2) for glioblastoma specific gene expression. The in vitro studies showed that the rPOA formed stable complexes with pEpo-NI2-SV-TK. In the MTT and TUNEL assays, rPOA showed lower cytotoxicity than polyethylenimine (25 kDa, PEI25k). In addition, the rPOA/pEpo-NI2-SV-TK complex induced higher glioblastoma cell death under hypoxic condition than normoxic condition, suggesting that pEpo-NI2-SV-TK induced gene expression in the hypoxic tumor tissue. For invivo therapeutic efficacy evaluation, the rPOA/pEpo-NI2-SV-TK complex was injected into the brains of an intracranial glioblastoma rat model. The rPOA/pEpo-NI2-SV-TK injected group had a significantly reduced tumor size, compared with the control and the PEI25k/pEpo-NI2-SV-TK injected group. The TUNEL assay showed that the rPOA-pEpo-NI2-SV-TK complex had more apoptotic cells than the control and PEI25k/pEpo-NI2-SV-TK injected groups. These results suggest that the rPOA is an efficient carrier for pEpo-NI2-SV-TK and increased the therapeutic efficacy in the intracranial glioblastoma models. Therefore, the rPOA/pEpo-NI2-SV-TK complex may be useful for glioblastoma specific gene therapy. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3743-3751, 2015 | en_US |
dc.description.sponsorship | This work was financially supported by the grant from Ministry of Health and welfare in Korea (grant number HI12C1210). | en_US |
dc.language.iso | en | en_US |
dc.publisher | WILEY-BLACKWELL | en_US |
dc.subject | cancer | en_US |
dc.subject | gene delivery | en_US |
dc.subject | gene therapy | en_US |
dc.subject | polymeric drug carrier | en_US |
dc.subject | polymeric drug delivery systems | en_US |
dc.title | Reducible Poly(Oligo-d-Arginine) as an Efficient Carrier of the Thymidine Kinase Gene in the Intracranial Glioblastoma Animal Model | en_US |
dc.type | Article | en_US |
dc.relation.no | 11 | - |
dc.relation.volume | 104 | - |
dc.identifier.doi | 10.1002/jps.24576 | - |
dc.relation.page | 3743-3751 | - |
dc.relation.journal | JOURNAL OF PHARMACEUTICAL SCIENCES | - |
dc.contributor.googleauthor | Kim, Hyun Ah | - |
dc.contributor.googleauthor | Lee, Hyun-Lin | - |
dc.contributor.googleauthor | Choi, Eunji | - |
dc.contributor.googleauthor | Kim, Yong-Hee | - |
dc.contributor.googleauthor | Lee, Minhyung | - |
dc.relation.code | 2015001455 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF ENGINEERING[S] | - |
dc.sector.department | DEPARTMENT OF BIOENGINEERING | - |
dc.identifier.pid | minhyung | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.